Ex-Pharmacyclics team raises $33.5M for checkpoint drug

Richard Miller

Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals. Dow Jones reports on the Burlingame, CA-based biotech's plans after its $33.5 million venture round, which was led by OrbiMed. Central to its future is a checkpoint inhibitor, which Miller says targets a new and undisclosed protein. Miller created the company with the help of another ex-Pharmacyclics exec, Joseph Buggy, and OrbiMed Private Equity Partner Peter Thompson. A Phase Ib study is expected to get started in early 2016. Story

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.